NEW YORK (GenomeWeb News) – Vermillion said today that its Aspira Labs subsidiary has received its clinical laboratory permit for the state of New York.

With the New York permit, Aspira is now licensed in all states requiring licensing, allowing the company to process Vermillion's OVA1 ovarian cancer test nationwide.

The permit also marks a milestone in the company's efforts to transition OVA1 testing from Quest Diagnostics to Aspira, which is a key aspect of its new commercial strategy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.